www.klinickafarmakologie.cz / KlinFarmakol Farm2021; 35(4): 118–123 / KLINICKÁ FARMAKOLOGIE A FARMACIE 123 ORIGINÁLNÍ PRÁCE Nové trendy v přístupu k léčbě diabetu 2. typu – postřehy a benefity v ambulantní praxi diabetologa 6. Yandrapalli S, Malik A, Horblitt A, et al. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. Cardiol Rev 2020;28(5):219–235. 7. Sachinidis A, Nikolic D, Stoian AP, et al. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP4 inhibitors. Metabolism 2020;111:154343. Epub 2020 Aug 16. 8. Pinto LC, Rados DV, Remonti LR, et al. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. J Clin Endocrinol Metab 2020;105(11):dgaa534. 9. Fillit HM, Rockwood K, Young JB. Brocklehurst‘s Textbook of Geriatric Medicine and Gerontology. Seventh ed. Philadelphia, Elsevier Health Sciences, 2016:1119. 10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl. 1):S111–S124. 11. Bhatt AS, Luo N, Solomon N, et al. TECOS Study Group. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. Am Heart J 2019;218:57–65. 12. Singh AK, Singh R. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Rev Clin Pharmacol 2017;10(4):429–442. 13. Mohammedi K, Woodward M, Hirakawa Y, et al. ADVANCE Collaborative Group. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol 2016;15(1):129. 14. Anděl M, Němcová V, Pavlíková N, et al. Faktory vedoucí k poškození a destrukci B-buněk Langerhansových ostrůvků pankreatu. Vnitř Lék 2014;60(9):684–690. 15. Charytan DM, Solomon SD, Ivanovich P, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2019;21(5):1199–1208. 16. Fayfman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care 2019;42(3):450–456. 17. Mo D, Liu S, Ma H, et al. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study. Drug Des Devel Ther 2019;13:2769–2776. 18. Frias JP, Zimmer Z, Lam RLH, et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab 2019;21(5):1128–1135. 19. Müller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab 2018;20(11):2598–2607. 20. Matthews DR, Paldanius PM, Proot P, et al. Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin- -metformin combination in newly diagnosed Type 2 diabetes. Diabet Med 2019;36(4):505–513. 21. Jia S, Wang Z, Ruobing Han 1, et al. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis. Acta Diabetol 2021;58(1):5–18. 22. Negro R, Greco EL, Greco G. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients. Exp Clin Endocrinol Diabetes 2019;127(4):215–219. 23. Gutierrez JA, Scirica BM, Bonaca MP, et al. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in atients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol 2019;123(1):145–152. 24. Mosenzon O, Leibowitz G, Bhatt DL et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care 2017;40(1):69–76. 25. Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet. 2015;385(9982):2067–2076. 26. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res 2015;12(3):164–174. 27. Rosenstock J, Perkovic V, Johansen OE. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019;321(1):69–79. 28. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16(11):642–653. 29. Chun-Xing Li, Shuo Liang, Lingyan Gao, Hua Liu. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One. 2021;16(2):e0244689. eCollection 2021. 30. Leite KM, Long AM, Ostroff ML, Borges L, Braden G. A Review of the Renoprotective Effects of Novel Antidiabetic Agents. J Pharm Pract 2021;34(1):141–148. 31. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation 2019;139(11):1384–1395. 32. Mahaffey KW, Neal B, Perkovic V, et al. CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018;137(4):323–334. 33. Wiviott SD, Raz I, Bonaca MP et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 2018;200:83–89. 34. Bae JH, Eun-Gee Park, Kim S, Kim SM, Hahn S, Kim NH. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Endocrinol Metab (Seoul) 2021;36(2):388–400. 35. Linong Ji, Xiaolin Dong, Yiming Li et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab 2021;23(2):404–414. 36. Mather KJ, Considine RV, Hamilton L, et al. Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes. J Clin Endocrinol Metab 2018;103(9):3456–3465. 37. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 2019;139(17):2022–2031. 38. Liu X, Huang J, Li J, Mao Q, He J. Effects of Liraglutide Combined with Insulin on Oxidative Stress and SerumMCP1 and NF-kB Levels in Type 2 Diabetes. J Coll Physicians Surg Pak 2019;29(3):218–221. 39. Ba J, Han P, Yuan G, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes 2017(7):667–676. 40. Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A „promised land“ in the COVID-19 era? J Diabetes Complications 2020; 34(12): 107723. Epub 2020 Aug 26. 41. Yan Yang, Zixin Cai, Jingjing Zhang. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta- -analysis. PLoS One. 2021;16(5):e0251916. eCollection 2021. 42. Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12(9):649–658. Epub 2020 May 27.
RkJQdWJsaXNoZXIy NDA4Mjc=